Inpai Pharma 07630Stock Information

Stock Information · New Rules (after Aug 2025)
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
// Company Overview //
Stock NameInpai Pharma
Stock Code07630
Company Full NameInpai Pharma
Industry生物医药
Principal Activities我們是一家處於商業化階段的生物技術公司，致力於在全球範圍內推進基於合成致死機制的精準抗癌療法，打造創新療法，以滿足癌症患者未被滿足的醫療需求。
Listing Date2026-05-13
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省南京市高新技術產業開發區星火路10號
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websiteimpacttherapeutics.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo
// Offering Information //
Offering Mechanism 机制B
Clawback Tiers机制B不设回拨，公开发售占比维持10.0%
Offer Period2026-05-05 to 2026-05-08
Offer PriceHK$ 20.10 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 4,020
Par ValueRMB 1.0 / shares
Global Offering Shares41,977,000
HK Public Offering Shares4,197,800 (10.0%)
International Placing Shares— (0.0%)
Offer Ratio~15.2%
Total Shares Post-IPO276,165,130 shares
Total Global Offering SizeHK$ 843,737,700
Public Offering SizeHK$ 84,375,780 (10.0%)
Oversubscription Multiple2,282.4x
Valid Applications221,788
Accepted Applications18,774
ReallocationNo
Total Funds RaisedHK$ 84,375,780
Greenshoe (Over-allotment Option)No
Final Public Offering Share10.0%
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 5,550,919,113
Pre-IPO Valuation (Last Round)No data
P/E Ratio不適用（公司處於虧損狀態）
Profit/Loss Status虧損人民幣295.9百萬元
Period-End Cash Balance人民币230,100,000元
Listing Expenses~HK$ 84,200,000
Listing Expenses / Funds RaisedNo data
Total Pre-IPO InvestmentNo data
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 35.5
First Day Change108.26%
First Day Volume15135000.0
First Day Turnover544227000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約51%或398.37百萬港元將用于為核心產品塞納帕利正在進行及計劃中的臨床開發、監管批準以及商業化提供資金； 2、約31%或242.15百萬港元將用于為關鍵產品IMP1734及IMP9064正在進行的臨床開發提供資金； 3、約8%或62.49百萬港元將用于為其他管線資產、IMP1707、IMP7068、IMP22、IMP25、IMP08、IMP13及IMP10的研發活動提供資金； 4、約8%或62.49百萬港元將用于為研發平臺的開發及擴大藥物管線提供資金； 5、約2%或15.62百萬港元將用于營運資金及其他一般公司用途。
// Underwriting Syndicate //
联席保荐人 (2)
高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司
保荐人兼整体协调人 (1)
高盛（亚洲）有限责任公司
整体协调人 (3)
高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司 招银国际融资有限公司
联席全球协调人 (3)
高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司 招银国际融资有限公司
联席账簿管理人 (4)
高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司 招银国际融资有限公司 老虎证券（香港）环球有限公司
联席牵头经办人 (4)
高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司 招银国际融资有限公司 老虎证券（香港）环球有限公司
资本市场中介人 (4)
高盛（亚洲）有限责任公司 中国国际金融香港证券有限公司 招银国际融资有限公司 老虎证券（香港）环球有限公司
// Service Providers //
RoleInstitution
本公司法律顾问 科律香港律师事务所
君合律师事务所
保荐人/包销商法律顾问 Kirkland & Ellis
天元律师事务所
核数师兼申报会计师 安永会计师事务所
行业顾问 弗若斯特沙利文（北京）咨询有限公司上海分公司
合规顾问 浤博资本有限公司
收款银行 招商永隆银行有限公司
H股证券登记处 香港中央证券登记有限公司
// Cornerstone Investors // Allotment Results Announcement
#Investor NameShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 DechengIMPACTLimited 23,559,685 8.53% — 2027-05-12 2027-05-12
2 廣西騰訊創業投資有限公司 15,593,533 5.65% — 2027-05-12 2027-05-12
3 上海禮瀚生物科技合夥企業 14,640,236 5.30% — 2027-05-12 2027-05-12
4 LAVEnterprise 14,220,861 5.15% — 2027-05-12 2027-05-12
5 BOUNDLESSCREEK,LLC 10,875,618 3.94% — 2027-05-12 2027-05-12
6 LAVInnovation(Hong 8,789,975 3.18% — 2027-05-12 2027-05-12
7 蘇州高特佳信銀匯鑫股權投資 8,615,202 3.12% — 2027-05-12 2027-05-12
8 蔡遂雄 8,422,233 3.05% — 2027-05-12 2027-05-12
9 田野 8,422,233 3.05% — 2027-05-12 2027-05-12
10 蘇州禮瑞股權投資中心（有限 8,368,406 3.03% — 2027-05-12 2027-05-12
11 揚州國金英派生物醫藥創業投 7,944,585 2.88% — 2027-05-12 2027-05-12
12 上海君實生物醫藥科技股份有 7,907,133 2.86% — 2027-05-12 2027-05-12
13 LAVIntegraLimited（「LAV 6,846,397 2.48% — 2027-05-12 2027-05-12
14 LAVImpetusLimited（「LAV 6,725,827 2.44% — 2027-05-12 2027-05-12
15 上海康鋆企業管理諮詢合夥企 6,030,649 2.18% — 2027-05-12 2027-05-12
16 北京新動力股權投資基金（有 6,030,642 2.18% — 2027-05-12 2027-05-12
17 蘇州禮康股權投資中心（有限 5,139,637 1.86% — 2027-05-12 2027-05-12
18 泰客戶TRS而言） 4,775,600 1.73% — 2026-11-12 2026-11-12
19 上海譽楠企業管理合夥企業 4,580,233 1.66% — 2027-05-12 2027-05-12
20 武漢光谷生物城華嶺基金合夥 4,362,991 1.58% — 2027-05-12 2027-05-12
21 海南躍馬爭春創業投資中心 4,307,601 1.56% — 2027-05-12 2027-05-12
22 杭州萬全島生物醫藥科技合夥 4,274,984 1.55% — 2027-05-12 2027-05-12
23 廈門建發新興產業股權投資柒 4,013,156 1.45% — 2027-05-12 2027-05-12
24 EverspringGQInvestment 3,664,188 1.33% — 2027-05-12 2027-05-12
25 廣州越秀生物產業創業投資基 3,588,778 1.30% — 2027-05-12 2027-05-12
26 上海華嶺智新投資合夥企業 3,558,211 1.29% — 2027-05-12 2027-05-12
27 黃河 3,117,800 1.13% — 2026-11-12 2026-11-12
28 黃河投資有限公司（「黃 3,117,800 7.43% 1.13% — —
29 無錫藥明康德一期投資企業 3,029,306 1.10% — 2027-05-12 2027-05-12
30 杭州千溪山生物醫藥科技合夥 2,986,905 1.08% — 2027-05-12 2027-05-12
31 BaoJun 2,767,497 1.00% — 2027-05-12 2027-05-12
32 共青城瑞吉三期投資合夥企業 2,372,140 0.86% — 2027-05-12 2027-05-12
33 ChinaSummitCapitalLimited 2,290,117 0.83% — 2027-05-12 2027-05-12
34 HomericSummitCapital 2,290,117 0.83% — 2027-05-12 2027-05-12
35 上海禮灝生物科技合夥企業 2,290,116 0.83% — 2027-05-12 2027-05-12
36 DingxinCapitalBiotech 2,290,116 0.83% — 2027-05-12 2027-05-12
37 EagleMindInvestments 2,290,116 0.83% — 2027-05-12 2027-05-12
38 蘇州工業園區新建元生物創業 2,134,448 0.77% — 2027-05-12 2027-05-12
39 杭州海邦藥谷從正創業投資合 2,134,448 0.77% — 2027-05-12 2027-05-12
40 蘇州禮潤股權投資中心（有限 2,125,370 0.77% — 2027-05-12 2027-05-12
41 VisionFund1 993,800 0.36% — 2026-11-12 2026-11-12
42 Vision Fund 1 SP 993,800 2.37% 0.36% — —
43 LAVStar 974,200 0.35% — 2026-11-12 2026-11-12
44 LAVOpportunities 974,200 0.35% — 2026-11-12 2026-11-12
45 FirstQuarterMoonOFC–PhecdaFund 974,200 0.35% — 2026-11-12 2026-11-12
46 ProsperHigh 776,000 0.28% — 2026-11-12 2026-11-12
47 GSCFund1 565,000 0.20% — 2026-11-12 2026-11-12
48 WWHCP 389,600 0.14% — 2026-11-12 2026-11-12
49 HorizonFund1 194,800 0.07% — 2026-11-12 2026-11-12
50 HorizonNextFund 194,800 0.07% — 2026-11-12 2026-11-12
51 Horizon Fund 1 SP 194,800 0.46% 0.07% — —
52 于慶貞 39,722 0.01% — 2027-05-12 2027-05-12
// Directors & Management //
Chairman徐聰
Company Secretary韓一凡
執行董事 (3)
#NameEnglish NameType
1 蔡遂雄 — 執行董事
2 田野 — 執行董事
3 马宁 — 執行董事
非執行董事 (3)
#NameEnglish NameType
1 徐聪 — 非執行董事
2 Qiang XU — 非執行董事
3 刘涛 — 非執行董事
獨立非執行董事 (3)
#NameEnglish NameType
1 郭明 — 獨立非執行董事
2 萧志雄 — 獨立非執行董事
3 邵黎明 — 獨立非執行董事
// Major Shareholders //
Major Shareholders & Holdings施毅博士透過LAV實體持有38,470,660股H股（13.93%）；上海禮曜投資管理有限公司及陳飛博士透過上海禮瀚等實體持有32,563,765股H股（11.79%）；Decheng IMPACT Limited持有23,559,685股H股（8.53%）；騰訊控股有限公司持有19,365,333股H股（7.01%）。
// Allotment Benchmarks //
Pool A (Small Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
200 67,375 1,010 0.01
400 31,423 487 0.02
600 7,145 114 0.02
800 4,135 68 0.02
1,000 5,633 96 0.02
1,200 2,889 51 0.02
1,400 2,481 45 0.02
1,600 2,331 43 0.02
1,800 2,223 43 0.02
2,000 21,604 422 0.02
3,000 5,244 115 0.02
4,000 6,287 153 0.02
5,000 2,883 77 0.03
6,000 1,867 55 0.03
7,000 1,308 41 0.03
8,000 1,141 39 0.04
9,000 1,085 40 0.04
10,000 7,202 282 0.04
20,000 6,048 380 0.06
30,000 4,890 424 0.09
40,000 4,190 463 0.12
50,000 2,441 328 0.12
60,000 1,914 302 0.15
70,000 1,434 260 0.17
80,000 1,524 313 0.20
90,000 1,259 289 0.23
100,000 8,062 2,041 0.25
200,000 5,128 2,514 0.50
Pool B (Large Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
300,000 5,016 3,182 0.60
400,000 1,603 1,199 0.80
500,000 903 778 0.75
600,000 503 503 0.90
700,000 397 33 1.05
800,000 250 50 1.20
900,000 184 57 1.35
1,000,000 444 191 1.50
1,250,000 227 162 1.87
1,500,000 148 148 2.25
1,750,000 127 35 2.62
2,098,800 840 572 3.15
Allotment Benchmarks
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics